<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03514446</url>
  </required_header>
  <id_info>
    <org_study_id>H-17027414</org_study_id>
    <secondary_id>2017-003529-13</secondary_id>
    <nct_id>NCT03514446</nct_id>
  </id_info>
  <brief_title>Seven Versus Fourteen Days of Treatment in Uncomplicated Staphylococcus Aureus Bacteremia</brief_title>
  <acronym>SAB7</acronym>
  <official_title>Efficacy of Seven and Fourteen Days of Antibiotic Treatment in Uncomplicated Staphylococcus Aureus Bacteremia: A Randomized, Non-blinded, Non-inferiority Interventional Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Benfield</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction: Staphylococcus aureus bacteremia (SAB) plays an important role in long-course
      antibiotic therapy. Current international guidelines recommend fourteen days of intravenous
      antibiotic treatment for SAB in order to minimize risks of secondary deep infections and
      complications. However, patients with simple SAB are known to have a low risk of
      complications. Reducing treatment length in uncomplicated SAB would reduce the total
      consumption of antibiotics, adverse events and duration of hospital admission. SAB7 seeks to
      determine if seven days of antibiotic treatment in patients with uncomplicated SAB is
      non-inferior to fourteen days of treatment.

      Method: The study is designed as a randomized, non-blinded, non-inferiority interventional
      study. Primary measure of outcome will be failure to treatment or recurrence of SAB twelve
      weeks after termination of antibiotic treatment. As a measure of secondary outcome the
      prevalence of severe adverse effects will be evaluated, in particular secondary infection
      with Clostridium difficile, mortality as well as public health related costs. Patients
      identified with uncomplicated SAB, are randomized 1:1 in two parallel arms to seven or
      fourteen days of antimicrobial treatment, respectively. Endpoints will be tested with a
      statistical non-inferiority margin of 10%.

      Conclusion: SAB 7 will determine if seven days of antibiotic treatment in patients with
      uncomplicated SAB is sufficient and safe, potentially modifying current treatment
      recommendations.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2018</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>90-day survival without clinical or microbiological failure to treatment or relapse</measure>
    <time_frame>up to 90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microbiologically failure to treatment</measure>
    <time_frame>less than 7 days after treatment termination</time_frame>
    <description>Verified S. aureus infection of the same genotype as the initial infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiologically relapse</measure>
    <time_frame>more than 7 days after treatment termination</time_frame>
    <description>Verified S. aureus infection of the same genotype as the initial infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical failure to treatment or relapse</measure>
    <time_frame>Up to day 90</time_frame>
    <description>Initiation of anti-staphylococcal therapy for more than 48 hours due to suspected recurrence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Days 14, 28, 90 and 180</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe adverse events</measure>
    <time_frame>Up to 26 weeks</time_frame>
    <description>grade 3 or above adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute renal injury</measure>
    <time_frame>Up to 26 weeks</time_frame>
    <description>A 1.5 fold increase in creatinine or a 25% decrease of the glomerular filtration rate (GFR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clostridium difficile infection</measure>
    <time_frame>Up to 26 weeks</time_frame>
    <description>Microbiologically verified C. difficile infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multidrug-resistance organism</measure>
    <time_frame>Up to 26 weeks</time_frame>
    <description>Microbiologically verified multidrug-resistance organism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-associated costs</measure>
    <time_frame>Up to 26 weeks</time_frame>
    <description>Public health related cost estimated from a general consideration of the expenses associated with hospitalization for SAB.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">284</enrollment>
  <condition>Staphylococcus Aureus Bacteremia</condition>
  <arm_group>
    <arm_group_label>Antibiotic therapy duration for 7 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Antibiotic therapy duration for 14 days</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antibiotic therapy duration for 7 days</intervention_name>
    <description>Antibiotic therapy for seven days</description>
    <arm_group_label>Antibiotic therapy duration for 7 days</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Blood culture positive for Staphylococcus aureus

          -  Antibiotic treatment with antimicrobial activity to S. aureus administrated within 12
             hours of the first positive blood culture

          -  Temperature &lt; 37,5 degrees celsius at randomization

          -  S. aureus negative follow-up blood culture obtained 48-96 hours after microbiological
             verified SAB.

          -  Patients written consent obtained

        Exclusion Criteria:

          -  Persistence of S. aureus bacteremia before randomization (S. aureus positive follow-up
             blood culture obtained 48-96 hours of the first positive blood culture)

          -  Polymicrobial infection

          -  Antibiotic treatment whit no antimicrobial activity to S. aureus administrated more
             than 12 hours of the first positive blood culture

          -  Endocarditis or other intracardiac infection demonstrated with transthoracic or
             transesophageal echocardiography

          -  Previous history of endocarditis

          -  Pacemaker or other intracardiac implant

          -  Failure to remove a likely focus of infection, such as central venous catheter within
             72 hours of the first positive blood culture.

          -  Prosthetics in joints and bones or vascular grafts

          -  Pneumonia or infection involving bone or joints

          -  Previously bone/join infection

          -  S. aureus infection within the last 90 days

          -  Pregnancy or breastfeeding

          -  Neutropenia (blood neutrophils &lt; 1,0 x 109/l)

          -  Untreated cancer

          -  Chemotherapy within 90 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Louise Thorlacius-Ussing, MD</last_name>
    <phone>+45 26457710</phone>
    <email>louise.thorlacius-ussing@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas Benfield, MD, DMSc</last_name>
    <email>Thomas.Lars.Benfield@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hvidovre Hospital</name>
      <address>
        <city>Hvidovre</city>
        <state>Copenhagen</state>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Louise Ussing, MD</last_name>
      <phone>26457710</phone>
      <email>louise.thorlacius-ussing@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm</url>
  </link>
  <reference>
    <citation>Banaei N, Anikst V, Schroeder LF. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015 Jun 11;372(24):2368-9. doi: 10.1056/NEJMc1505190.</citation>
    <PMID>26061852</PMID>
  </reference>
  <reference>
    <citation>Kaasch AJ, Fätkenheuer G, Prinz-Langenohl R, Paulus U, Hellmich M, Weiß V, Jung N, Rieg S, Kern WV, Seifert H; SABATO trial group (with linked authorship to the individuals in the Acknowledgements section). Early oral switch therapy in low-risk Staphylococcus aureus bloodstream infection (SABATO): study protocol for a randomized controlled trial. Trials. 2015 Oct 9;16:450. doi: 10.1186/s13063-015-0973-x.</citation>
    <PMID>26452342</PMID>
  </reference>
  <reference>
    <citation>Thwaites GE, Edgeworth JD, Gkrania-Klotsas E, Kirby A, Tilley R, Török ME, Walker S, Wertheim HF, Wilson P, Llewelyn MJ; UK Clinical Infection Research Group. Clinical management of Staphylococcus aureus bacteraemia. Lancet Infect Dis. 2011 Mar;11(3):208-22. doi: 10.1016/S1473-3099(10)70285-1. Review.</citation>
    <PMID>21371655</PMID>
  </reference>
  <reference>
    <citation>Blyth CC, Darragh H, Whelan A, O'Shea JP, Beaman MH, McCarthy JS. Evaluation of clinical guidelines for the management of Staphylococcus aureus bacteraemia. Intern Med J. 2002 May-Jun;32(5-6):224-32.</citation>
    <PMID>12036220</PMID>
  </reference>
  <reference>
    <citation>Benfield T, Espersen F, Frimodt-Møller N, Jensen AG, Larsen AR, Pallesen LV, Skov R, Westh H, Skinhøj P. Increasing incidence but decreasing in-hospital mortality of adult Staphylococcus aureus bacteraemia between 1981 and 2000. Clin Microbiol Infect. 2007 Mar;13(3):257-63.</citation>
    <PMID>17391379</PMID>
  </reference>
  <reference>
    <citation>Zeylemaker MM, Jaspers CA, van Kraaij MG, Visser MR, Hoepelman IM. Long-term infectious complications and their relation to treatment duration in catheter-related Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis. 2001 Jun;20(6):380-4.</citation>
    <PMID>11476436</PMID>
  </reference>
  <reference>
    <citation>Raad II, Sabbagh MF. Optimal duration of therapy for catheter-related Staphylococcus aureus bacteremia: a study of 55 cases and review. Clin Infect Dis. 1992 Jan;14(1):75-82.</citation>
    <PMID>1571466</PMID>
  </reference>
  <reference>
    <citation>Fowler VG Jr, Sanders LL, Sexton DJ, Kong L, Marr KA, Gopal AK, Gottlieb G, McClelland RS, Corey GR. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Clin Infect Dis. 1998 Sep;27(3):478-86.</citation>
    <PMID>9770144</PMID>
  </reference>
  <reference>
    <citation>Mylotte JM, McDermott C, Spooner JA. Prospective study of 114 consecutive episodes of Staphylococcus aureus bacteremia. Rev Infect Dis. 1987 Sep-Oct;9(5):891-907. Review.</citation>
    <PMID>3317734</PMID>
  </reference>
  <reference>
    <citation>Ehni WF, Reller LB. Short-course therapy for catheter-associated Staphylococcus aureus bacteremia. Arch Intern Med. 1989 Mar;149(3):533-6.</citation>
    <PMID>2919931</PMID>
  </reference>
  <reference>
    <citation>Larsen AR, Stegger M, Sørum M. spa typing directly from a mecA, spa and pvl multiplex PCR assay-a cost-effective improvement for methicillin-resistant Staphylococcus aureus surveillance. Clin Microbiol Infect. 2008 Jun;14(6):611-4. doi: 10.1111/j.1469-0691.2008.01995.x. Epub 2008 Apr 3.</citation>
    <PMID>18393997</PMID>
  </reference>
  <reference>
    <citation>Mejer N, Westh H, Schønheyder HC, Jensen AG, Larsen AR, Skov R, Benfield T; Danish Staphylococcal Bacteraemia Study Group. Stable incidence and continued improvement in short term mortality of Staphylococcus aureus bacteraemia between 1995 and 2008. BMC Infect Dis. 2012 Oct 17;12:260. doi: 10.1186/1471-2334-12-260.</citation>
    <PMID>23075215</PMID>
  </reference>
  <reference>
    <citation>Mylotte JM, McDermott C. Staphylococcus aureus bacteremia caused by infected intravenous catheters. Am J Infect Control. 1987 Feb;15(1):1-6.</citation>
    <PMID>3645972</PMID>
  </reference>
  <reference>
    <citation>Iannini PB, Crossley K. Therapy of Staphylococcus aureus bacteremia associated with a removable focus of infection. Ann Intern Med. 1976 May;84(5):558-60.</citation>
    <PMID>1275357</PMID>
  </reference>
  <reference>
    <citation>Jensen AG, Wachmann CH, Espersen F, Scheibel J, Skinhøj P, Frimodt-Møller N. Treatment and outcome of Staphylococcus aureus bacteremia: a prospective study of 278 cases. Arch Intern Med. 2002 Jan 14;162(1):25-32.</citation>
    <PMID>11784216</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2017</study_first_submitted>
  <study_first_submitted_qc>May 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2018</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Thomas Benfield</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacteremia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

